Willem Roosens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Willem Roosens has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Rik Schrijvers
Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group KU Leuven Leuven Belgium
2 shared publications Adrian Liston
Pathology Department University of Cambridge Cambridge UK
1 shared publicationCatho Colson
KU Leuven, Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group Leuven Belgium
1 shared publication- Cecilia Iglesias-Herrero
Advanced Disease Modelling, Targeted Drug Discovery and Gene Therapy (ADVANTAGE), Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium
1 shared publication Eric Legius
Department of Human Genetics, KU Leuven, Leuven, Belgium
1 shared publicationFrederik Staels
KU Leuven Department of Microbiology, Immunology and Transplantation Adaptive Immunology Laboratory Leuven Belgium
1 shared publication
Latest Publications
- Open Access
- 9 October 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (6)
JAK-inhibitor treatment induces rapid yet incomplete immune reconstitution in STAT1 gain-of-function
Autosomal dominant STAT1 gain-of-function (GOF) is an inborn error of immunity characterized by chronic mucocutaneous candidiasis and variable immune dysregulation. JAK inhibitors are a promising therapy, but their efficacy in STAT1 GOF remains variable. We longitudinally evaluated the clinical and molecular impact of JAK inhibitors in two STAT1 GOF patients, harboring p.R321S and p.T385M mutations, using Cellular Indexing of Transcriptomes and Epitopes by sequencing, flow cytometry, cytokine measurement, and allele-specific expression analysis in peripheral blood mononuclear cells and serum. Rapid yet incomplete immune reconstitution was observed as early as 1 week after treatment initiation. T cells rebalanced to a more homeostatic status and TCR repertoire diversity increased rapidly. However, some immune defects remained, including natural killer deficiency in one patient. The pronounced transcriptional dysregulation in monocytes was not explained by an unbalanced mutant STAT1 expression but improved with JAK-inhibitor treatment. JAK inhibitors provided significant clinical and immunological benefits to STAT1 GOF patients but did not fully restore immune homeostasis. These findings highlight the therapeutic potential and limitations of JAK inhibitors in STAT1 GOF.
- 9 October 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (6)
Open AccessJAK-inhibitor treatment induces rapid yet incomplete immune reconstitution in STAT1 gain-of-function
Autosomal dominant STAT1 gain-of-function (GOF) is an inborn error of immunity characterized by chronic mucocutaneous candidiasis and variable immune dysregulation. JAK inhibitors are a promising therapy, but their efficacy in STAT1 GOF remains variable. We longitudinally evaluated the clinical and molecular impact of JAK inhibitors in two STAT1 GOF patients, harboring p.R321S and p.T385M mutations, using Cellular Indexing of Transcriptomes and Epitopes by sequencing, flow cytometry, cytokine measurement, and allele-specific expression analysis in peripheral blood mononuclear cells and serum. Rapid yet incomplete immune reconstitution was observed as early as 1 week after treatment initiation. T cells rebalanced to a more homeostatic status and TCR repertoire diversity increased rapidly. However, some immune defects remained, including natural killer deficiency in one patient. The pronounced transcriptional dysregulation in monocytes was not explained by an unbalanced mutant STAT1 expression but improved with JAK-inhibitor treatment. JAK inhibitors provided significant clinical and immunological benefits to STAT1 GOF patients but did not fully restore immune homeostasis. These findings highlight the therapeutic potential and limitations of JAK inhibitors in STAT1 GOF.
- 22 May 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (10) , 2179-2181
Entering the era of somatic variant sequencing in immune dysregulation: comment on the article by Fu et al
- 22 May 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (10) , 2179-2181
Entering the era of somatic variant sequencing in immune dysregulation: comment on the article by Fu et al
- Open Access
- 27 September 2025
- Published by Elsevier in Trends in Immunology
- Vol. 47 (2) , 130-146
Emerging insights into mosaic errors of immunity
- 27 September 2025
- Published by Elsevier in Trends in Immunology
- Vol. 47 (2) , 130-146
Open AccessEmerging insights into mosaic errors of immunity
- Open Access
- 20 July 2025
- Published by Wiley in European Journal of Immunology
- Vol. 55 (7) , e70002
Homozygosity for the Common IL23R R381Q Variant Associates with Increased Susceptibility to Chronic Mucocutaneous Candidiasis
Chronic mucocutaneous candidiasis can be caused by an Inborn Error of Immunity, especially those affecting TH-17 / IL-17 responses. Through in-depth immunophenotyping and functional assays, we reveal the association between homozygous carriage of the common p.R381Q IL-23R genetic variant and increased candidiasis susceptibility, relying on disrupted IL-23-mediated IL-17 immunity.
- 20 July 2025
- Published by Wiley in European Journal of Immunology
- Vol. 55 (7) , e70002
Open AccessHomozygosity for the Common IL23R R381Q Variant Associates with Increased Susceptibility to Chronic Mucocutaneous Candidiasis
Chronic mucocutaneous candidiasis can be caused by an Inborn Error of Immunity, especially those affecting TH-17 / IL-17 responses. Through in-depth immunophenotyping and functional assays, we reveal the association between homozygous carriage of the common p.R381Q IL-23R genetic variant and increased candidiasis susceptibility, relying on disrupted IL-23-mediated IL-17 immunity.